Intratio
Loading...
Skip to main content
Model output · Signal date 2026-10-16

Utah Medical Products Inc (UTMD) Stock Forecast Oct. 16, 2026

Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq

Follow Unlock full AI forecasts
Rating · 90D ▼ Bearish Exact rating locked
90-day forecast Sign up free to reveal
30-day forecast Total
Rank in coverage Bottom 35% of 5121 stocks scored
Rank correlation · 90D 41.0% Spearman, 357 dates
Market Cap $239M small-cap · #60 of 60 peers
Summary

Utah Medical Products Inc (UTMD) stock forecast summary

Our AI ranks Utah Medical Products Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

Utah Medical Products Inc is a small-cap company with a market capitalization of $239M. It ranks number 60 by market capitalization among the 60 Surgical & Medical Instruments & Apparatus issuers in our coverage with a current forecast. Its Net Margin of 29.0% is the highest of the 43 peers that report one. Its Current Ratio of 48.62x is the highest of the 59 peers that report one.

For UTMD, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 41.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 21.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.6%, buy ≥ +3.2%, sell < +1.9%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-15 signals)

A free account shows the exact forecast, rating and rank of 3 tickers you follow, UTMD included.

Follow UTMD free
Price

UTMD price chart and AI forecast

UTMD
Cross-section · 2026-10-15

How UTMD ranks among 5121 stocks

90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Fundamentals · 2026-06-30

Utah Medical Products Inc (UTMD) fundamentals

Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Surgical & Medical Instruments & Apparatus peers listed below that report each metric.

Valuation & Market

MetricUTMDIndustry medianRank
Market Cap $239M $1.42B 60/60
P/E Ratio 22.19x 29.88x 20/26
P/B Ratio 1.95x 4.52x 48/55
Dividend Yield 1.65% 1.38% 4/11
EPS $3.38 – –
Book Value/Share $38.33 – –
Revenue/Share $11.34 – –
FCF/Share $3.60 – –

Profitability & Margins

MetricUTMDIndustry medianRank
ROE 8.6% -2.8% 18/41
ROA 8.4% -2.7% 13/44
ROIC 8.4% -1.1% 18/53
Gross Margin 57.9% 65.0% 37/53
Operating Margin 28.4% 1.0% 5/54
Net Margin 29.0% -1.2% 1/43
EBT Margin 35.7% 0.2% 3/54
Tax Rate 18.6% – –

Financial Health

MetricUTMDIndustry medianRank
Current Ratio 48.62x 3.85x 1/59
Quick Ratio 44.27x 2.51x 1/55
D/E Ratio 0.02x 0.63x 56/56
Financial Leverage 1.02x 1.63x 54/54
Interest Coverage 58.6x 0.4x 5/48
Working Capital $99M $227M 43/59

Cash Flow

MetricUTMDIndustry medianRank
Operating Cash Flow $12M $42M 33/55
Free Cash Flow $11M $7M 25/50
Capital Spending -$400K -$16M 5/50
OCF Growth YoY -16.2% 17.0% 27/34
FCF Growth YoY -17.0% 20.6% 20/26
FCF/Sales 31.7% 1.6% 1/49
CapEx/Sales 1.1% 3.6% 41/49

Operational Efficiency

MetricUTMDIndustry medianRank
Asset Turnover 0.29x 0.72x 47/50
Receivables Turnover 10.1x 6.5x 3/51
Inventory Turnover 1.7x 1.9x 33/51
Fixed Assets Turnover 3.8x 6.3x 38/52
Days Sales Outstanding 36 days 56 days 49/51
Days Inventory 216 days 187 days 19/51
Payables Period 21 days 51 days 45/46
Cash Conversion Cycle 231 days 192 days 14/42

Income Statement

MetricUTMDIndustry medianRank
Total Revenue $36M $622M 50/52
Operating Income $10M -$2M 26/55
Net Income $10M -$5M 20/44
R&D Expense $690K $61M 53/53
SG&A Expense $11M $319M 53/53
Cost of Goods Sold $15M $167M 48/53

Dividend & Shareholder Information

MetricUTMDIndustry medianRank
Dividends Per Share $1.24 – –
Payout Ratio 36.7% 36.7% 5/9
Shares Outstanding 3M – –
Net Income Growth -16.5% 12.3% 16/20
EPS Growth 19.4% 15.6% 10/22

Balance Sheet Highlights (USD millions)

Total Current Assets$101M80.8% of assets
Cash & Short-term Investments$88M70.3% of assets
Accounts Receivable$4M2.9% of assets
Inventory$9M7.2% of assets
Total Liabilities$3M2.0% of assets
Short-term Debt$1M1.0% of assets
Quarterly Financial Reports

UTMD quarterly financials and insider trading

Industry Peers · Surgical & Medical Instruments & Apparatus

Utah Medical Products Inc (UTMD) industry peers

Companies classified under the same SEC industry code as Utah Medical Products Inc (Surgical & Medical Instruments & Apparatus): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Reveal all forecasts · See exact % predictions for all competitors

Sign up free
Company 90-Day AI Forecast (Total) Market Cap P/E Ratio P/B Ratio
UTMD Utah Medical Products Inc ▼ $239M 22.2x 2.0x
SYK Stryker Corp ▼ $112.48B 30.4x 4.7x
MMM 3m Co ▶ $85.26B 29.4x 28.9x
BSX Boston Scientific Corp ▼ $63.97B 21.9x 2.6x
BDX Becton Dickinson & Co ▼ $52.78B 62.9x 2.2x
MDLN Medline Inc. ▶ $48.08B – 4.2x
RMD Resmed Inc ▼ $34.94B 23.2x 5.3x
DXCM Dexcom Inc ▼ $33.10B 38.5x 12.6x
WST West Pharmaceutical Services Inc ▼ $26.96B 49.0x 9.0x
SOLV Solventum Corp ▼ $14.96B 9.9x 3.1x
BAX Baxter International Inc ▶ $13.32B – 2.2x
PEN Penumbra Inc ▼ $12.65B 98.8x 8.3x
GMED Globus Medical Inc ▼ $10.59B 22.3x 5.3x
GKOS Glaukos Corp ▲ $9.77B – 14.3x
PODD Insulet Corp ▼ $9.62B 23.8x 6.8x
HAE Haemonetics Corp ▼ $5.52B 58.6x 6.6x
TFX Teleflex Inc ▼ $5.43B – 1.9x
MMSI Merit Medical Systems Inc ▼ $5.35B 40.0x 3.2x
STVN Stevanato Group S.P.A. ▲ $5.26B 8.4x –
MMED Minimed Group, Inc. ▶ $5.06B – 1.4x
HTFL Heartflow, Inc. ▲ $4.43B – 15.8x
ICUI Icu Medical Inc/De ▼ $4.18B 298.6x 1.9x
IRTC Irhythm Holdings, Inc. ▼ $3.60B – 19.4x
PLSE Pulse Biosciences, Inc. ▲ $3.25B – 32.7x
ATRC Atricure, Inc. ▶ $2.94B 825.4x 5.7x
UFPT Ufp Technologies Inc ▶ $2.30B 32.1x 5.0x
INSP Inspire Medical Systems, Inc. ▲ $2.03B 14.0x 2.5x
LMAT Lemaitre Vascular Inc ▼ $1.90B 31.3x 4.5x
KMTS Kestra Medical Technologies, Ltd. ▲ $1.71B – 7.7x
ATEC Alphatec Holdings, Inc. ▲ $1.69B – –
NVCR Novocure Ltd ▲ $1.68B – 5.0x
DRTS Alpha Tau Medical Ltd. ▲ $1.16B – 15.0x
TNDM Tandem Diabetes Care Inc ▲ $1.15B – 8.8x
IRMD Iradimed Corp ▼ $1.14B 52.3x 11.2x
AORT Artivion, Inc. ▼ $1.07B – 2.4x
IART Integra Lifesciences Holdings Corp ▶ $1.05B – 1.0x
PRCT Procept Biorobotics Corp ▲ $1.04B – 3.1x
BVS Bioventus Inc. ▼ $943M 20.0x 4.1x
BBNX Beta Bionics, Inc. ▲ $913M – 3.6x
SIBN Si-Bone, Inc. ▶ $892M – 4.9x
SGP Spyglass Pharma, Inc. ▲ $827M – 3.6x
MDXG Mimedx Group, Inc. ▶ $682M 29.3x 3.2x
KIDS Orthopediatrics Corp ▼ $589M – 1.7x
SSII Ss Innovations International, Inc. ▲ $541M – 10.1x
TCMD Tactile Systems Technology Inc ▼ $528M 22.8x 2.4x
DCTH Delcath Systems, Inc. ▲ $523M 211.6x 4.3x
ANGO Angiodynamics Inc ▲ $487M – 3.0x
SGHT Sight Sciences, Inc. ▲ $485M – 9.2x
BWAY Brainsway Ltd. ▲ $463M – –
CERS Cerus Corp ▲ $455M – 6.5x
NPCE Neuropace Inc ▶ $439M – 36.9x
RCEL Avita Medical, Inc. ▲ $415M – –
OFIX Orthofix Medical Inc. ▼ $391M – 0.9x
CARL Carlsmed, Inc. ▲ $381M – 4.5x
EMBC Embecta Corp. ▶ $365M 5.4x –
OBIO Orchestra Biomed Holdings, Inc. ▲ $345M – 17.9x
CLPT Clearpoint Neuro, Inc. ▲ $294M – 27.3x
ANIK Anika Therapeutics, Inc. ▼ $277M – 2.0x
MOBI Mobia Medical, Inc. ▼ $277M – 1.6x
TMCI Treace Medical Concepts, Inc. ▲ $268M – 4.0x

Where UTMD sits on the market map

Industrial Applications and Services · Surgical & Medical Instruments & Apparatus
Explore the map →
News

Utah Medical Products Inc (UTMD) stock news

More news available

Sign up free to read all 10 news articles and stay updated on market developments.

Sign Up Free to Read More
FAQ

Utah Medical Products Inc (UTMD) stock forecast FAQ

What is the Utah Medical Products Inc (UTMD) stock forecast?

Our AI ranks Utah Medical Products Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

How accurate are Utah Medical Products Inc stock predictions?

For UTMD, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 41.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 21.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

How often are Utah Medical Products Inc forecasts updated?

Utah Medical Products Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.

Which companies are Utah Medical Products Inc's industry peers?

60 issuers in our coverage, UTMD included, share the SEC industry code Surgical & Medical Instruments & Apparatus. The largest are: Stryker Corp (SYK), 3m Co (MMM), Boston Scientific Corp (BSX), Becton Dickinson & Co (BDX), Medline Inc. (MDLN), Resmed Inc (RMD).

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.